Top Cefuroxime Brands: A Guide to Quality and Reliability

Cefuroxime, a widely used antibiotic medication, is essential for treating a variety of bacterial infections. Numerous pharmaceutical companies manufacture this important drug, offering different formulations and price points. In recent years, certain brands have stood out due to their efficacy, affordability, and availability. To discover the top-rated brands of cefuroxime that cater to diverse needs, check out the detailed list below.

Illustration of cefuroxime

Best brands of cefuroxime in 2025

GlaxoSmithKline

GlaxoSmithKline (GSK) is a leading producer of cefuroxime, a second-generation cephalosporin antibiotic, known for its broad-spectrum activity against various bacterial infections. In 2020, GSK's cefuroxime brands, such as Zinnat, had combined sales of approximately USD 140 million in relevant markets. The global cefuroxime powder for injection market, which includes GSK's products, is projected to grow significantly, driven by the rising incidence of bacterial infections and the need for effective antibiotic treatments. GSK's commitment to innovative R&D and its strong manufacturing capabilities ensure high-quality antibiotic products. The company's divestment of its Cephalosporin antibiotics business to Sandoz in 2021 did not impact its ongoing research and development in innovative antibiotics. For more detailed insights, you can view the GSK AMR Benchmark Scorecard.

Sandoz

Sandoz, a Novartis division, has solidified its position as a leading producer of cefuroxime and other cephalosporin antibiotics through its acquisition of GSK's cephalosporin business, which includes the global rights to established brands like Zinnat, Zinacef, and Fortum in over 100 markets. This move complements Sandoz's leadership in generic penicillins and reinforces its commitment to antibiotics, with the acquired brands generating approximately $140 million in sales in 2020. The transaction, valued at $350 million plus up to $150 million in milestone payments, is expected to enhance Sandoz's global antibiotics production, particularly at its integrated manufacturing site in Kundl, Austria. Sandoz's strategy includes a four-year manufacturing and supply agreement with GSK to ensure a smooth transition of manufacturing operations. This acquisition aligns with Sandoz's goal to expand its antibiotics portfolio, driving market growth in a sector expected to register a CAGR of 2.75% from 2022 to 2027. For more details, visit their official announcement page.

Lupin Pharmaceuticals

Lupin Pharmaceuticals is a leading producer of cefuroxime axetil, having received USFDA approval for its generic equivalent of GlaxoSmithKline's Ceftin® tablets in 2003. This approval marked Lupin's first finished product approval in the US market, with the product manufactured at their facility in Mandideep, India. The market size of cefuroxime axetil was estimated at US $310 million as of December 2002. Lupin has since expanded its generic portfolio, receiving over 250 FDA approvals and marketing 180 generic products, solidifying its position as one of the fastest-growing pharmaceutical companies in the US. The company's strong presence in the generics market is supported by its vertically integrated operations and robust pipeline. For more details about their generic product offerings, you can visit their website.

Aurobindo Pharma

Aurobindo Pharma is a leading manufacturer of generic pharmaceuticals, including cefuroxime, with a strong presence in over 150 countries and more than 90% of its revenues derived from international operations. The company manufactures more than 99% of its active pharmaceutical ingredients (APIs) in-house and has a robust product portfolio that includes 32 antibacterial medicines, among which cefuroxime is a key product. Aurobindo's cefuroxime axetil tablets are manufactured in facilities approved by regulatory bodies such as the US FDA, UK MHRA, and EMA, ensuring high-quality standards. Between April 2020 and March 2021, Aurobindo reached 600,000 patients in Vietnam with its generic versions of essential medicines, including antibiotics like cefuroxime. The company's commitment to quality and safety is evident through its periodic risk-based audits and compliance with international GMP standards.

Teva Pharmaceuticals

Teva Pharmaceuticals stands as a leading producer of cefuroxime, a second-generation cephalosporin antibiotic, with a strong presence in the global market. In 2023, Teva reported a 7% increase in revenues in local currency terms, driven in part by higher revenues from generic products, including antibiotics like cefuroxime. The company's generics business, which includes cefuroxime, saw a significant boost, with generic product revenues in the United States segment increasing by 30% in the third quarter of 2024. Teva's global network of over 53 manufacturing facilities in more than 33 countries enables it to produce approximately 76 billion tablets and capsules annually, ensuring widespread availability of essential medications like cefuroxime. With its commitment to quality and innovation, Teva continues to be a major player in the cephalosporin drugs market. Learn more about Teva's impact and capabilities.

Mylan

Mylan, now part of Viatris, is a leading global pharmaceutical company renowned for its extensive portfolio of high-quality medicines, including cefuroxime sodium. Viatris, formed through the combination of Mylan and Pfizer's Upjohn division, is committed to expanding access to medicines and innovating to meet patient needs. With a workforce of approximately 35,000, Viatris markets its products in over 165 countries and territories, making it one of the largest producers of active pharmaceutical ingredients. The company's generics segment, which includes cefuroxime sodium, performed ahead of expectations in 2023, contributing to total net sales of $15.4 billion for the year. Viatris's strong global presence and commitment to quality ensure reliable access to essential medications like cefuroxime sodium. For more information, visit the Viatris website.

Zydus Cadila

Zydus Cadila is a renowned pharmaceutical company known for its high-quality generic medications, including cefuroxime, a widely used antibiotic. The company has a significant presence in the global pharmaceutical market, with its products available in 50 countries. In the context of cefuroxime, Zydus Cadila's formulations, such as cefuroxime tablets and injections, are priced competitively, with ceiling prices regulated by authorities to ensure affordability, for example, as seen in the National Pharmaceutical Pricing Authority (NPPA) guidelines. Zydus Cadila's commitment to producing high-quality, low-cost generic drugs has contributed to its reputation as a leader in the pharmaceutical industry. The company's growth is supported by its robust research and development facilities, including an R&D facility in Atlanta.

Cipla

Cipla, a leading Indian multinational pharmaceutical company, is renowned for its high-quality production of cefuroxime axetil tablets, among other pharmaceuticals. With over 50 years of experience in manufacturing APIs and formulations, Cipla has established itself as a global leader, supplying products to 86 countries. The company's state-of-the-art manufacturing facilities are cGMP compliant and approved by major international regulatory agencies, including the US FDA and WHO. Cipla's commitment to affordability and innovation has been evident, such as its significant contribution to making antiretroviral drugs accessible at a fraction of the cost. In fiscal year 2024, Cipla generated 43% of its revenue from the Indian market and 30% from North America, highlighting its strong global presence.

Granules India

Granules India is recognized as a prominent producer of cefuroxime, particularly for its high-quality cefuroxime axetil granules. These granules are formulated to mask the bitterness of cefuroxime axetil, ensuring high stability and bioavailability. The production process involves mixing sucrose fatty acid ester and methacrylic acid-ethylacrylate copolymer, followed by dispersing a disintegrating agent and non-crystalline cefuroxime axetil, resulting in granules with improved pharmacokinetic properties. This method enhances the bioavailability of cefuroxime axetil, reaching up to 52% when taken after food. The granules are also designed to disintegrate efficiently, making them suitable for oral administration.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd. is a leading producer of cefuroxime, a crucial antibiotic, with a strong global presence and over 40 manufacturing facilities. Founded in 1983, Sun Pharma has grown to become the fourth largest specialty generic pharmaceutical company worldwide, with global revenues of US$ 5.4 billion. The company's API manufacturing capabilities, including cefuroxime axetil, are supported by European approvals and USFDA certifications, ensuring high-quality and compliant products. Sun Pharma's extensive product portfolio includes over 2000 high-quality molecules, and it supplies medicines to more than 100 countries. The company invests up to 6-8% of its global revenues in Research and Development, further enhancing its capabilities in developing complex pharmaceutical products. For more detailed information about their offerings, visit the Sun Pharmaceutical Industries API portfolio.